Author

L. Portelance

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:spatial domain detection· 1

Frequent Co-Authors

A.-M. Mes-Masson· 2 shared D. Provencher· 2 shared E. Carmona· 2 shared F. Rodier· 2 shared J. Lafontaine· 2 shared K. Rahimi· 2 shared M. Skulimowski· 2 shared S. Cheng· 2 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A.-M. Mes-Masson

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 30, 2023

A senescence-like state is beneficial for ovarian cancer treatment

M. Skulimowski, L. Calvo Gonzalez, S. Cheng…·F. Rodier

This study shows that senescence in ovarian cancer cells after chemotherapy correlates with better patient survival, suggesting senescence could be a therapeutic target.

DOI 10.1101/2023.09.30.560300

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 24, 2018

Cellular senescence is a central response to cytotoxic chemotherapy in high-grade serous ovarian cancer

L. Calvo, S. Cheng, M. Skulimowski…·F. Rodier

The paper shows that chemotherapy induces cellular senescence in high-grade serous ovarian cancer, which correlates with better patient survival.

DOI 10.1101/425199

humanbulk RNA-seq

𝕏 PostBluesky